Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)

Trial Profile

Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)

Phase of Trial: Phase III

Latest Information Update: 10 Dec 2007

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Atenolol
  • Indications Atherosclerosis; Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms MORE
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 10 Dec 2007 Positive results have been published.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top